Seeking to mitigate increasing supply chain risks, pharmaceutical companies have identified “China Plus One” as a strategic imperative. Under this risk-management model, companies diversify their supply chains to include at least one other country in addition to China, allowing them to continue benefitting from China’s manufacturing footprint while avoiding the risks associated with relying solely on one country.
